

CLINICAL PAYMENT, CODING AND POLICY CHANGES

NEW POLICY UPDATES – EFFECTIVE NOVEMBER 1, 2019:

In an effort to keep our providers informed we regularly augment our clinical, payment and coding policy positions as part of our ongoing policy review processes. Please see the chart below for upcoming new policies or changes.

Changes below are effective for dates of service beginning November 1, 2019:

Drugs and Biologicals Policies:

Aetna Better Health of Pennsylvania supports FDA label, off-label compendia (Micromedex, Clinical Pharmacology, National Comprehensive Cancer Network, Lexi-Drugs, American Hospital Formulary Service Drug Information®), AMA/ CPT, state Medicaid guidelines and other sources for Drugs and Biologicals.

These supported policies include:

- Indication (FDA-label and off-label approved compendia indications)
- Dosage (based on indication and supported by FDA-label and off-label approved compendia)
- Frequency (based on indication and supported by FDA-label and off-label approved compendia)
- Route of administration (based on category of drug, FDA-label, off-label approved compendia, and AMA/CPT guidelines)
- Age restrictions
- Combination therapy with other required drugs/substances (based on FDA-label and approved off-label compendia guidelines by indication)

New Drug/Biological Policies:

- Palonosetron HCl (J2469)
- Epoetin Alfa (ESRD) (Q4081, Q5105)
- Ferumoxytol (Q0138) (Non-ESRD Use)
- Iron Dextran (J1750)
- Iron Sucrose (J1756)
- Intrauterine Contraceptive Systems and Contraceptive Implants (J7296, J9297, J7298, J7300, J7301, J7307)